Printer Friendly

IMMUNOGEN, IC. ANNOUNCES THAT PHASE III TRIAL OF ONCOLYSIN B WILL BEGIN SOON

 CAMBRIDGE, Mass., Jan. 27 /PRNewswire/ -- ImmunoGen, Inc. (NASDAQ: IMGN) announced today that the company will begin a Phase III trial of its lead product, Oncolysin B, soon after the signing of an agreement with a nationally recognized oncology group. Contract negotiations are near completion. This pivotal study is designed to evaluate the effectiveness of Oncolysin B in B-cell lymphoma patients who are in clinical remission following bone marrow transplantation. It will measure the improvement in disease-free survival (time to relapse) in patients treated with Oncolysin B versus an equal number of patients who do not receive the drug.
 "Follow-up of patients in our early trials using Oncolysin B continues to indicate that the drug may be very effective to consolidate remission in lymphoma patients and extend their disease-free interval subsequent to bone marrow transplantation," states Mitchel Sayare, chairman and chief executive officer. "We are excited about the initiation of this Phase III study, which we expect will yield data sufficient for product license. We are near completion of the complex and time-consuming process required to standardize a single protocol across more than 25 treatment centers. The basic trial design was approved by the Food and Drug Administration last May. The company is ready to begin patient enrollment and will ship Oncolysin B to the centers involved in the study immediately upon signing of the agreement and approval by the centers' Institutional Review Boards."
 ImmunoGen, Inc. develops innovative therapeutics for the treatment of cancer and immune-mediated diseases. The company produces proprietary toxins conjugated to highly specific targeting agents which search out and destroy cancer cells. The company's first-generation products, the Oncolysins, are each comprised of a highly specific monoclonal antibody linked to blocked ricin, a proprietary derivative of the powerful plant toxin, ricin.
 -0- 1/27/93
 /CONTACT: Mark Ratner, director of external communications for ImmunoGen, 617-661-9312/
 (IMGN)


CO: ImmunoGen, Inc. ST: Massachusetts IN: MTC SU:

DH-SJ -- NE007 -- 9641 01/27/93 12:07 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1993
Words:324
Previous Article:UNOCAL LAUNCHES CHAKACHATNA PROJECT
Next Article:SUTTER HEALTH, EJ FINANCIAL ENTERPRISES FORM NEW SURGERY COMPANY;
Topics:


Related Articles
RESULTS OF PHASE I/II TRIALS USING IMMUNOGEN'S ONCOLYSIN B SHOW POTENTIAL FOR PREVENTING RELAPSE IN CANCER PATIENTS
IMMUNOGEN COMPLETES PHASE I TRIAL OF ONCOLYSIN S
IMMUNOGEN BEGINS PHASE II TRIALS OF ONCOLYSIN S
IMMUNOGEN'S ONCOLYSIN B CONTINUES TO PREVENT RELAPSES IN LYMPHOMA PATIENTS
LIDAK PHARMACEUTICALS RECEIVES FDA CLEARANCE TO PROCEED WITH CANCER THERAPY CLINICAL TRIALS
Immunogen Ends Development Of Oncolysin B

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters